Scholarlink

Purpose of Review <p>Advances in radiation therapy techniques that allow for better normal tissue sparing have made reirradiation (reRT) a more viable option for managing locoregional recurrences in various cancers. However, severe toxicity and a high risk of second recurrence persist, emphasizing the need for improved patient selection and treatment planning. This scoping review, registered in the PROSPERO database (CRD42023387364), followed PRISMA guidelines. A thorough search was conducted from 2012 to December 2023 in MEDLINE (via PubMed) and BioMed Central databases, focusing on studies that reported the value of multimodal imaging in enhancing patient selection and optimizing reRT planning. Inclusion criteria targeted studies involving MRI and PET imaging, with exclusions based on relevance, language, and quality.</p> Recent Findings <p>Of 363 records identified, 29 studies met inclusion criteria. Most focused on high-grade glioma (HGG, 48%), head and neck cancer (HNC, 31%), and pelvic cancer (21%). In HGG, <sup>18</sup>F-FET PET and GdT1w-MRI linked larger, metabolically active volumes with shorter overall survival (OS). Radiomic signatures from pre-reRT PET/MRI, extracted from the planned reRT volume, were associated with post-reRT recurrence, reflecting the prognostic value of intratumoral heterogeneity. Multimodal imaging differentiated disease progression from post-treatment changes, aiding target delineation. Techniques like <sup>11</sup>C-MET PET, <sup>18</sup>F-FET PET, and diffusion-weighted imaging for HGG, as well as <sup>18</sup>F-FDG PET and dynamic contrast imaging for HNC, enhanced target definition and enabled dose-painting. MRI-guided reRT reduced urinary toxicity in prostate cancer through precise treatment adaptation.</p> Summary <p>Multimodal imaging is essential for patient selection, target delineation, and adaptive reRT in recurrent cancers. Further research and standardization are needed to maximize its clinical impact.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review

  • 期刊论文

  • 发表日期：

    2025年8月20日

查看全文
  • Arnaud Beddok,
  • Laura Rozenblum,
  • Valentin Calugaru,
  • Loic Feuvret,
  • Laurence Champion,
  • Catherine Ala Eddine,
  • Gilles Crehange,
  • Georges El Fakhri,
  • Irène Buvat

摘要

Purpose of Review

Advances in radiation therapy techniques that allow for better normal tissue sparing have made reirradiation (reRT) a more viable option for managing locoregional recurrences in various cancers. However, severe toxicity and a high risk of second recurrence persist, emphasizing the need for improved patient selection and treatment planning. This scoping review, registered in the PROSPERO database (CRD42023387364), followed PRISMA guidelines. A thorough search was conducted from 2012 to December 2023 in MEDLINE (via PubMed) and BioMed Central databases, focusing on studies that reported the value of multimodal imaging in enhancing patient selection and optimizing reRT planning. Inclusion criteria targeted studies involving MRI and PET imaging, with exclusions based on relevance, language, and quality.

Recent Findings

Of 363 records identified, 29 studies met inclusion criteria. Most focused on high-grade glioma (HGG, 48%), head and neck cancer (HNC, 31%), and pelvic cancer (21%). In HGG, 18F-FET PET and GdT1w-MRI linked larger, metabolically active volumes with shorter overall survival (OS). Radiomic signatures from pre-reRT PET/MRI, extracted from the planned reRT volume, were associated with post-reRT recurrence, reflecting the prognostic value of intratumoral heterogeneity. Multimodal imaging differentiated disease progression from post-treatment changes, aiding target delineation. Techniques like 11C-MET PET, 18F-FET PET, and diffusion-weighted imaging for HGG, as well as 18F-FDG PET and dynamic contrast imaging for HNC, enhanced target definition and enabled dose-painting. MRI-guided reRT reduced urinary toxicity in prostate cancer through precise treatment adaptation.

Summary

Multimodal imaging is essential for patient selection, target delineation, and adaptive reRT in recurrent cancers. Further research and standardization are needed to maximize its clinical impact.